PFKFB3 and neoplasm: The glycolytic activator PFKFB3 was shown to regulate not only endothelial cell proliferation but also cytoskeletal rearrangements required for vessel sprouting, and the inhibition of PFKFB3 was shown to reduce pathological ocular angiogenesis and normalize tumor vessels, improving chemotherapy and inhibiting metastasis [126,127,128].